Table 3

Clinic-based secondary outcome variables (all Honevo minus control)

Comparison	N with data		Hodges-Lehman estimate (95% CI)	p Value
Comparison	Honevo	Control	Hodges-Lehman estimate (95% CI)	p Value
IGA-RSS week 2	66	66	0 (−1 to 0)	0.26
IGA-RSS week 8	61	54	0 (−1 to 0)	0.06
IGA-RSS week 2 minus baseline	66	66	−1 (−1 to 0)	0.03
IGA-RSS week 8 minus baseline	61	54	−1 (−1 to 0)	0.005

			Estimate (95% CI)	p Value

IGA-RSS week 8 adjusted for baseline*	61	54	−0.6 (−1.1 to −0.2)	0.003

			Mean difference (95% CI)	p Value

VAS-CS week 2	66	66	9.1 (3.5 to 14.7)	0.002
VAS-CS week 8	61	54	12.3 (5.7 to 18.9)	<0.001
VAS-S week 2	66	66	−3.6 (−9.9 to 2.7)	0.26
VAS-S week 2 minus baseline	66	66	−2.9 (−9.2 to 3.5)	0.38
VAS-S week 8	61	54	−4.5 (−11.6 to 2.6)	0.21
VAS-S week 8 minus baseline	61	54	−11.0 (−18.0 to −3.9)	0.003

IGA-RSS: blinded Investigator Global Assessment of Rosacea Severity Score, based on a seven-point scale (0 ‘clear’ to 6 ‘severe’).
VAS-CS: Participant-rated assessment of change in severity of rosacea based on a 100 mm VAS scale (0 mm ‘much worse’ to 100 mm ‘much improved’).
VAS-S: Participant-rated assessment of severity of rosacea based on a 100 mm VAS scale (0 mm ‘mildest possible’ symptoms and 100 mm ‘worst possible’ symptoms).
Analysis of variance (ANOVA) with baseline reading as a covariate, normality assumptions not well met.
*ANOVA with baseline reading as a co-variate, normality assumptions not well met.